- Home
- IGMS vs VERU Comparison
IGMS vs VERU Comparison
Compare IGMS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- VERU
- Stock Information
- Founded
- IGMS 1993
- VERU 1971
- Country
- IGMS United States
- VERU United States
- Employees
- IGMS N/A
- VERU N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- VERU Health Care
- Exchange
- IGMS Nasdaq
- VERU Nasdaq
- Market Cap
- IGMS 81.9M
- VERU 85.5M
- IPO Year
- IGMS 2019
- VERU 1990
- Fundamental
- Price
- IGMS $1.27
- VERU $0.56
- Analyst Decision
- IGMS Hold
- VERU Strong Buy
- Analyst Count
- IGMS 8
- VERU 2
- Target Price
- IGMS $6.00
- VERU $4.00
- AVG Volume (30 Days)
- IGMS 1.3M
- VERU 2.2M
- Earning Date
- IGMS 08-13-2025
- VERU 08-07-2025
- Dividend Yield
- IGMS N/A
- VERU N/A
- EPS Growth
- IGMS N/A
- VERU N/A
- EPS
- IGMS N/A
- VERU N/A
- Revenue
- IGMS $2,681,000.00
- VERU $16,886,419.00
- Revenue This Year
- IGMS $252.44
- VERU N/A
- Revenue Next Year
- IGMS $46.48
- VERU N/A
- P/E Ratio
- IGMS N/A
- VERU N/A
- Revenue Growth
- IGMS 27.36
- VERU 134.43
- 52 Week Low
- IGMS $0.92
- VERU $0.45
- 52 Week High
- IGMS $22.50
- VERU $1.42
- Technical
- Relative Strength Index (RSI)
- IGMS 48.73
- VERU 44.48
- Support Level
- IGMS $1.26
- VERU $0.57
- Resistance Level
- IGMS $1.37
- VERU $0.62
- Average True Range (ATR)
- IGMS 0.03
- VERU 0.04
- MACD
- IGMS -0.01
- VERU -0.00
- Stochastic Oscillator
- IGMS 8.33
- VERU 20.80
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.